Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB cut its stake in Apogee Therapeutics, Inc. (NASDAQ:APGE) by 14.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,500 shares of the company’s stock after selling 1,300 shares during the quarter. Handelsbanken Fonder AB’s holdings in Apogee Therapeutics were worth $340,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. New York State Common Retirement Fund grew its position in shares of Apogee Therapeutics by 8.9% in the fourth quarter. New York State Common Retirement Fund now owns 12,187 shares of the company’s stock valued at $552,000 after purchasing an additional 1,000 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of Apogee Therapeutics by 3.4% during the 4th quarter. Rhumbline Advisers now owns 52,720 shares of the company’s stock worth $2,388,000 after buying an additional 1,750 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Apogee Therapeutics by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,547 shares of the company’s stock valued at $432,000 after buying an additional 892 shares during the period. SG Americas Securities LLC lifted its holdings in Apogee Therapeutics by 22.2% in the fourth quarter. SG Americas Securities LLC now owns 9,890 shares of the company’s stock valued at $448,000 after acquiring an additional 1,796 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Apogee Therapeutics by 4.3% in the third quarter. JPMorgan Chase & Co. now owns 29,555 shares of the company’s stock worth $1,736,000 after acquiring an additional 1,212 shares during the period. 79.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on APGE. Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $89.00 price objective on the stock. Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Wedbush reissued an “outperform” rating and issued a $90.00 price target on shares of Apogee Therapeutics in a research report on Monday. Finally, Canaccord Genuity Group initiated coverage on shares of Apogee Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $89.00 price target for the company. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $89.71.

Apogee Therapeutics Trading Down 0.2 %

Shares of NASDAQ:APGE opened at $31.39 on Tuesday. The firm has a 50 day simple moving average of $40.01 and a 200-day simple moving average of $47.32. The company has a market capitalization of $1.41 billion, a PE ratio of -12.97 and a beta of 2.18. Apogee Therapeutics, Inc. has a twelve month low of $29.64 and a twelve month high of $72.29.

Apogee Therapeutics (NASDAQ:APGE) last announced its earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.25). As a group, equities research analysts predict that Apogee Therapeutics, Inc. will post -3.09 EPS for the current fiscal year.

Insider Activity at Apogee Therapeutics

In related news, CEO Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $46.58, for a total value of $698,700.00. Following the sale, the chief executive officer now directly owns 1,324,487 shares in the company, valued at $61,694,604.46. The trade was a 1.12 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Carl Dambkowski sold 6,665 shares of the company’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $46.07, for a total value of $307,056.55. Following the transaction, the insider now directly owns 260,798 shares in the company, valued at $12,014,963.86. This represents a 2.49 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 63,810 shares of company stock worth $2,903,556 in the last quarter. Company insiders own 36.10% of the company’s stock.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.